Literature DB >> 1164612

Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.

F R Ellis, I M Clarke, M Modgill, S Currie, D G Harriman.   

Abstract

Evidence is presented that serum creatinine phosphokinase (CPK) activity is of no direct value in screening patients for susceptibility to malignant hyperpyrexia and does not correlate with halothane-induced muscle contracture or the presence of myopathy. Widely differing CPK values were found at different times in the same people. In most "malignant hyperpyrexia" families the susceptible patients had either normal or inconsistently raised CPK values.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1164612      PMCID： PMC1674333          DOI： 10.1136/bmj.3.5982.511

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  2 in total

Review 1.  Malignant hyperthermia: a statistical review.

Authors:  B A Britt; W Kalow
Journal:  Can Anaesth Soc J       Date:  1970-07

2.  Malignant hyperpyrexia myopathy.

Authors:  D G Harriman; D W Sumner; F R Ellis
Journal:  Q J Med       Date:  1973-10
  2 in total
  5 in total

1.  The anaesthetic management of the malignant hyperthermia susceptible parturient.

Authors:  M J Douglas; G H McMorland
Journal:  Can Anaesth Soc J       Date:  1986-05

Review 2.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

3.  [A case of malignant hyperthermia occuring in a dental clinic].

Authors:  A Martel; L Spigelblatt; L Perreault; R Rosenfeld
Journal:  Can Anaesth Soc J       Date:  1979-01

4.  Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility.

Authors:  P H Cribb; E A Olfert; F B Reynolds
Journal:  Can Vet J       Date:  1986-12       Impact factor: 1.008

5.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.